Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis

Figure 3

Forest plot analysis of lipase in patients treated with PD-1/CTLA-4 antibodies compared with control therapy. PD-1: chem: PD-1 inhibitor versus chemotherapy; CTLA-4: CTLA-4 inhibitor versus chemotherapy/placebo; CTLA-4 + PD1: nivolumab + ipilimumab subgroup versus nivolumab/ipilimumab; G1–5: grade1–5; G3–5: grade3–5.